payer relationships

2.26.2014 Account Strategy for Payer Organizations

Provide a Framework for New Product Planning Groups to Influence Clinical Trials

By Jacob Presson, Research Analyst A common theme running through a lot of what we at Cutting Edge Information learn while conducting research on the pharmaceutical industry is the need for more consistent and productive communication between internal...
 

1.8.2014 Clinical Development

Drug Safety Data and HEOR Driving Clinical Trial Costs and Time

By Ryan McGuire, Research Team Leader The healthcare marketplace has seen seismic shifts over the past five years.  Austerity measures have strained the reimbursement climate in many EU countries and driven government payers to scrutinize every...
 

11.14.2013 Managed Care Liaison / HOL

A Method to the Madness: Managed Markets Account Managers

By Jacob Presson, Research Analyst As payers demand ever-increasing evidence of product efficacy and cost effectiveness from the pharmaceutical industry, managing relationships with them is growing in strategic importance.  As a result, account...
 

9.24.2013 Medical Affairs

Great Moderators Key to Pharmaceutical Advisory Board Success

By Jacob Presson, Research Analyst Pharmaceutical companies are evolving their advisory board strategies to keep pace with the rapid changes that the entire industry is experiencing. As payer demands increase in complexity, the importance of engaging...
 

9.4.2013 Managed Care Liaison / HOL

Ideal Criteria for Finding Top-Notch Health Outcomes Liaisons

By Nicole May, Research Analyst With the expanding emphasis on building payer relationships and demonstrating product value, health outcomes liaison and managed care liaison teams are more important than ever.  The first step to building a strong...
 

8.13.2013 Managed Care Liaison / HOL

Want Top Formulary Postions? You’ll Need a Well-Armed Payer Liaison Team

By Nicole May, Research Analyst Payer meetings are crucial to drug success.  Payer liaison teams, whether they consist of health outcomes liaisons (HOL), managed care liaisons (MCL), or any other medical/economic expert team, must convince payers...
 

6.6.2013 Managed Care Liaison / HOL

Managed Care Liaisons Provide Growing Support to MCOs

By David Richardson, Research Manager At the recent World Congress event, “Thought Leader Engagement, The Role of Medical Affairs and Medical Science Liaisons in the Era of Healthcare Reform,” one of the topics of conversation revolved around...
 

6.4.2013 Clinical Development

Advisory Board Functions Expanding in Pharma Industry

By Jacob Presson, Research Analyst Advisory boards have been part of the pharmaceutical landscape for a long time, providing companies with valuable expert opinions on topics ranging from ensuring thorough regulatory submissions to clinical trial...
 

4.15.2013 Account Strategy for Payer Organizations

Projected Impact of ACA Legislation on Unpaid Hospital Bills

According to the American Hospital Association, hospitals nationwide remain liable for up to $41.1 billion in unpaid healthcare costs annually.  This cost is up from the recorded amount of outstanding costs in 2010 ($39.3 billion).  Currently, Jack Hadley, senior...
 

1.16.2013 New Product Development

New Product Planning Adapts to Payer Demands

Before prospective pharma products are even knee-deep into development, new product planning teams are tasked to start thinking about their commercialization. Tightening payer budgets and shifting reimbursement requirements are forcing teams to emphasize the value...